Publications
22 September 2025
Researchers identified METTL5 as a key driver of immune resistance in ovarian cancer. By altering rRNA methylation and ATF4 translation, METTL5 suppresses ferroptosis, reducing response to immunotherapy. Targeting this axis may enhance ICB efficacy.